Cancer Vaccines. from Research to Clinical Practice

Description

With the first therapeutic cancer vaccine approved by the FDA in April 2010, and other vaccines currently in the pipeline, the interest in this developing area is set to increase exponentially.

Breaking new grounds,Cancer Vaccines provides a state of the art perspective on a projected, rapidly growing field, and describes the successful journey of the first licensed therapeutic vaccines for cancer, from design to approval.

Written and edited by key personnel in industry and academia working within cancer vaccines development, this book is the result of a global collaborative effort integrating industry, academia, non-for profit, with participation from members of regulatory agencies.

Key features:

• Highlights major vaccines and platform technologies in early or late development, nearing approval
• Introduces emerging technologies that could yield novel classes of drugs bridging active and passive immunotherapies
• Provides an update of pipeline and approved cancer vaccines
• Encompasses both scientific, translational as well as development aspects
• Includes an introductory chapter on the immune systems role in cancer and a closing chapter on the challenges involved in cancer vaccine development

An essential read for:

• Cancer immunologists in academia and industry
• Drug developers in the area of oncology biotherapies
• Clinical physicians involved in clinical trials of cancer biotherapies
• Regulatory agencies

Contents

Preface
Foreword

1.Introduction - Cancer Vaccines: Mechanism and Clinical Overview
Antoni Ribas

2.Revisiting the Paradigm on the Putative Need for Antigen-Specific Responses in Cancer
Gail Sckisel, Julia Tietze, and William J. Murphy

GU Vaccines (Approved and In Development)

3.Development of Novel Immune Interventions for Genito-urinary Cancers
Neeraj Agarwal and Nicholas J. Vogelzang

4.Autologous Cellular Immunotherapy in Late-stage Prostate Cancer: Development History of Sipuleucel-T (Provenge®)
David Urdal and Mark W. Frohlich

5.Design, Development and Translation of Poxvirus-based Vaccines for Cancer
Benedetto Farsaci, Anna Kwilas, and James W. Hodge

Non-GU Vaccines (Approved and In Development)

6.Of Mice and Men (and Dogs!): First Approved Cancer Therapy Vaccine
Philip J. Bergman and Jedd D. Wolchok

7.Recombinant Protein Vaccination for Antigen Specific Cancer Immunotherapy
Pedro Miguel De Sousa Alves and Vincent Brichard

8.Antigen Targeted, Synthetic Vaccines for Metastatic Cancer
Zhiyong Qiu, David C. Diamond, Kent A. Smith, Dar Rosario, Sabrina Miles, Mihail Obrocea, and Adrian Bot

9.Clinical perspectives in Cancer Vaccines for Hematological Diseases
Maurizio Chiriva-Internati, Leonardo Mirandola, Marjorie Jenkins, Martin Cannon, Everardo Cobos, and W. Martin Kast

10.Epitope-based Vaccines for Cancer
Vy Lai, Denise L. Cecil, Gregory E. Holt, Daniel R. Herendeen, Forest Kievit, Miqin Zhang, and Mary L. Disis

Vaccine Development: Trial Design and Immune Assays

11.Emerging Clinical Trial Design Concepts for Therapeutic Cancer Vaccines
Christina Musselli, Leah Isakov, and Kerry Wentworth

12.T Cell Immune Monitoring Assays to Guide the Development of New Cancer Therapies
Cedrik Britten, Sylvia Janetzki, Cecile Gouttefangeas, Marij J.P. Welters, Michael Kalos, Christian Ottensmeier, Axel Hoos, and Sjoerd H. van der Burg

13.A Biomarker Based, Systems Biology Approach Guiding Development of Active Immunotherapies and Immune Monitoring
Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron, and Rafick-Pierre Sékaly

Emerging New Vaccine Strategies, Targets and Adjuvants

14.Targeting Regulatory T Cells and Other Strategies to Enable Cancer Vaccines
Christopher Paustian, Shawn M. Jensen, Sarah Church, Sachin Puri, Chris Twitty, Hong-Ming Hu, Brendan D. Curti, Walter J. Urba, and Bernard A. Fox

15.Molecular Targeting of Cancer Stem Cells
Zhenhua Li, Debraj Mukherjee, Jang-Won Lee, and John S. Yu

16.RNA in Cancer Vaccine Therapy
Smita Nair, David Boczkowski, Scott Pruitt, and Johannes Urban

17.Induction of Innate Immunity by Nucleic Acids: a Potential Adjuvant for Cancer Vaccines?
Bo Jin and Anthony E.T. Yeo

New Generation Hybrid Active/Passive Immunotherapies

18.Passive Immunotherapy by T Cell-engaging Bispecific Antibodies
Patrick A. Baeuerle and Benno Rattel

19.Antibodies to Peptide/HLA Complexes Have Potential Application for Cancer Diagnosis and Therapy
Jon A. Weidanz and William H. Hildebrand

Author Bio

Adrian Bot, MD, PhD, is a Vice President of Scientific Management at MannKind Corporation, Valencia, California. He was a Guest Scientist at the Scripps Research Institute in La Jolla and Scientist, Principal Scientist and Director of Immunology Research at Alliance Pharmaceutical Corp. in San Diego before joining Allecure Pharmaceuticals, then MannKind Corp as a Director of Research and Development. Dr. Adrian Bot’s background is in theoretical and experimental immunology, cancer research and drug development. He has authored and co-authored more than 70 peer-reviewed research articles, reviews, book chapters and monographs, in basic and applied immunology. Dr. Bot holds patents and patent applications on DNA vaccines, microparticle-based technologies, immune therapeutic approaches and innovative drugs in oncology and autoimmune diseases. He is on several scientific advisory panels, such as the Medical Science Review Committee of the Juvenile Diabetes Research Foundation. Dr. Bot was a former Associate Editor of Journal of Immunology and is the current Editor in Chief of the Informa Healthcare journal International Reviews of Immunology.

Mihail Obrocea, MD, is Vice President of Clinical Development, at MannKind Corporation, Valencia, California. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. During his career Dr Obrocea has worked for MedImmune Inc, Sigma-tau Research Inc and Pfizer Inc. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.

Francesco Marincola, MD, FACS, is Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health in Bethesda, Maryland. Dr. Marincola serves as the Editor-in-Chief, Journal of Translational Medicine; US Senior Editor of Immunotherapy, Associate Editor for The Journal of Immunotherapy and a former Section Editor for Informa Healthcare journal Expert Opinion in Biological Therapy. Dr. Marincola is an author of over 350 peer reviewed research articles and over 100 abstracts. He has been invited to speak at over 200 national and international meetings. Dr. Marincola is the second most cited scientist in melanoma during the last ten years, with 55 papers cited 3,704 times to date. Dr. Marincola’s record includes 63 papers cited a total of 2,955 times to date in the field of Clinical Medicine and 51 papers cited a total of 2,204 times to date in the field of Immunology.